Concierge medical retina · London
Eye injections for macular degeneration, by a consultant medical retina specialist.
Rapid-access wet AMD assessment, an honest choice between aflibercept, Eylea HD, faricimab and ranibizumab — and a treat-and-extend plan tailored to your OCT and your life.
Why patients choose us
- 01
A consultant medical retina specialist
Not a rotating trainee and not a generalist. A named retina consultant plans and delivers each intravitreal injection.
- 02
Treat-and-extend, not a one-size interval
Fixed 8- or 12-week schedules are the NHS default. We tailor intervals to your OCT and vision — 4 to 16 weeks, honestly reviewed.
- 03
Independent, and free
We are paid by no clinic, so the choice of drug and unit is impartial and costs you nothing.
Indicative pricing
What private eye injections for macular degeneration cost in the UK.
Indicative ranges across our partner medical retina units. Send the details and we quote firm figures across two or three options.
In short
One anti-VEGF injection in our network: £950–£1,900, home within the hour.
| Treatment | Indicative range | Typical duration | Time to next visit |
|---|---|---|---|
| Intravitreal aflibercept 2mg (Eylea) | £950–£1,400 | 30 min visit | Same visit |
| Intravitreal aflibercept 8mg (Eylea HD) | £1,400–£1,900 | 30 min visit | Same visit |
| Intravitreal faricimab (Vabysmo) | £1,200–£1,700 | 30 min visit | Same visit |
| Intravitreal ranibizumab (Lucentis) | £900–£1,300 | 30 min visit | Same visit |
| Loading course (3 injections, one eye) | £2,700–£5,400 | 3 monthly visits | Over 8–10 weeks |
| New-patient wet AMD assessment (OCT + OCT-A) | £350–£600 | 45–60 min | Same visit |
Prices vary by clinic, by which retina consultant delivers your care, by the anti-VEGF drug and dose, and by the OCT and imaging bundled into the visit. We come back with a firm quote within one working day.
The problem
The right diagnosis, the right drug, the right interval.
Wet AMD is time-critical, but most private pathways rely on fixed 8-week intervals and a single default drug. We fix diagnosis, drug choice and interval before you commit.
-
Sudden distortion this week?
A rapid-access wet AMD slot within 24–48 hours, with OCT on the day and — if needed — angiography.
-
Worried about the burden?
Aflibercept 8mg and faricimab can extend intervals to 12–16 weeks in many patients, honestly explained.
-
Already on injections?
A second opinion, a formal drug switch, or a review of whether your interval can safely extend.
The journey
From enquiry to treat-and-extend — what happens, in order.
One retina consultant from first message through loading course into your maintenance interval.
Phase 1 · Before your injection
Rapid-access diagnosis
Phase 2 · On the day
Under an hour in clinic
Phase 3 · After
Treat-and-extend
- 01
Before
You tell us what has changed
A short, confidential form. Sudden distortion, a missing patch of vision, an optometrist letter, or an existing wet AMD diagnosis.
- 02
Before
Rapid-access assessment within 24–48 hours
A retina clinic slot, OCT and — if needed — OCT angiography or fluorescein angiography to confirm neovascular AMD.
- 03
Before
A named drug plan and interval
Aflibercept, aflibercept 8mg, ranibizumab or faricimab — chosen on your lesion, comorbidity and lifestyle. Loading dose is booked.
- 04
On the day
Arrival at the injection suite
Drops to dilate and numb the eye, povidone-iodine prep, a small lid speculum. You are awake and comfortable throughout.
- 05
On the day
The injection itself
Under 30 seconds. A 30G needle enters the pars plana 3.5–4mm behind the limbus. Most people describe pressure, not pain.
- 06
On the day
Home within the hour
A short observation, written aftercare and floaters explained. You can be driven home or take a taxi — driving yourself depends on vision.
- 07
After
OCT-guided treat-and-extend
Three monthly loading doses, then intervals extended by two weeks while the retina stays dry — aiming for 12–16 weeks between visits.
Typical loading course: three injections over 8–10 weeks. Maintenance target: 12–16 weeks between visits.
When it helps
When anti-VEGF injections are the right treatment.
The retinal conditions we treat most, plus the red flag that means eye A&E — not a clinic booking.
-
Neovascular ("wet") AMD
New blood vessels leaking under the macula — the classic and commonest indication for anti-VEGF.
-
Diabetic macular oedema (DMO)
Central retinal swelling from diabetic retinopathy — anti-VEGF is first line for centre-involving DMO.
-
Retinal vein occlusion (RVO)
Macular oedema after branch or central retinal vein occlusion — treated on a similar treat-and-extend basis.
-
Myopic choroidal neovascularisation
New vessels in high myopia — a small number of injections often controls the disease long-term.
-
Distortion or a missing patch
Straight lines that bend, or a smudge in central vision, on your Amsler grid — assess within days, not weeks.
-
Established wet AMD on treatment
Already having injections and want a second opinion, a switch of drug, or a longer interval — we take these referrals.
-
Geographic atrophy (dry AMD)
Pegcetacoplan (Syfovre) may slow lesion growth — an honest conversation about likely benefit is essential.
-
Red flag: sudden vision loss
A sudden painful red eye after a recent injection, or a curtain across vision, is an emergency — same-day eye A&E, not a clinic booking.
Drug options
Anti-VEGF is not one drug — it is a family.
What each option on the table actually does, and which fits which patient.
-
Aflibercept 2mg (Eylea)
The workhorse anti-VEGF for wet AMD and DMO — proven durability at 8-week intervals in most patients after loading.
-
Aflibercept 8mg (Eylea HD)
Higher-dose aflibercept licensed 2023 — PULSAR/PHOTON data support intervals up to 20 weeks in responders.
-
Faricimab (Vabysmo)
Dual-action antibody targeting angiopoietin-2 and VEGF-A — YOSEMITE/RHINE show up to 16-week intervals for many patients.
-
Ranibizumab (Lucentis)
The original NICE-approved anti-VEGF — still used where aflibercept or faricimab is unsuitable, and in myopic CNV.
-
Pegcetacoplan (Syfovre)
For non-neovascular geographic atrophy — slows lesion growth but does not restore vision. Not for wet AMD.
-
Port delivery system (Susvimo)
A refillable ranibizumab implant giving 6-monthly refills — UK availability is limited and case-selected.
-
Second-opinion / switch clinic
Already on injections but plateauing, or intervals shortening — a formal review of the drug, the dose and the interval.
-
Consultation only
An honest assessment of whether injections are indicated, likely benefit and realistic burden — no obligation.
Our vetted UK network
A small panel of retina consultants, we picked them.
Consultant medical retina specialists across central, north, west and south London, plus regional partners. Not listed publicly — introductions are made privately, once we understand your case.
Selection criteria
How we choose every retina consultant in our network.
-
Consultant medical retina specialists, not general ophthalmologists
-
Dedicated intravitreal injection suite with sterile prep protocol
-
OCT and OCT-angiography on site for treat-and-extend decisions
-
Access to aflibercept 2mg, aflibercept 8mg, faricimab and ranibizumab
Safety and side effects
What to expect afterwards — honestly.
Intravitreal injections are one of the most-delivered eye procedures in the UK — over 800,000 a year in England. Serious complications are rare; knowing what is normal and what is not is what matters.
-
Endophthalmitis is rare but serious
A severe intraocular infection occurs after roughly 1 in 3,000–5,000 injections. Sudden pain, redness or worsening vision within days is an emergency — call the clinic or attend eye A&E.
-
Transient rise in eye pressure
Intraocular pressure rises briefly after every injection. Around 5% of patients need long-term pressure-lowering drops — checked on your review OCT visits.
-
Subconjunctival haemorrhage is common
A red patch on the white of the eye where the needle entered is cosmetic and settles in 1–2 weeks. It is not a sign of a bad injection.
-
Floaters and blurred vision for hours
New floaters and a haze from the povidone-iodine prep are expected on the day. Vision is usually back to your baseline by the following morning.
-
Traumatic cataract and retinal detachment
Both are uncommon — around 1 in 1,000–2,000 injections for detachment. Any curtain, flashes or sudden loss of vision needs urgent review.
-
Dry eye and injection fatigue are real
Repeated drops, prep and appointments wear people down. Compliance drops after year three — we plan intervals honestly with that in mind.
-
Systemic risk is small but monitored
The dose reaching the bloodstream is tiny, but rare cardiovascular events are noted per label. Your specialist reviews the balance if you have had a recent stroke or heart attack.
-
Povidone-iodine allergy — tell us
True povidone-iodine anaphylaxis is very rare but serious. If you have reacted before, chlorhexidine-based prep is used instead.
-
Red flags after an injection
Increasing pain, spreading redness, worsening vision or a curtain across sight in the days after an injection are not normal — seek same-day eye emergency care.
Reading your injection clinic note
Your clinic letter in four parts. Read the last one first.
Whichever drug is used, the letter your retina consultant sends after each injection keeps to the same shape.
A quiet reminder
Retina language is precise and can read coldly — we translate it for you.
If you would like us to talk you through the letter and OCT before your next visit, just ask.
- 01 Header
Diagnosis, eye treated and drug given
The indication (wet AMD, DMO, RVO, myopic CNV), which eye was injected, the drug, dose and batch number.
- 02 Technique
OCT findings and injection technique
Whether the OCT showed subretinal fluid, intraretinal fluid or a pigment epithelial detachment, and the site of the pars plana injection.
- 03 Findings
Anatomical response and visual acuity
How the retina is responding compared with the last visit, and the Snellen or ETDRS letter score in the treated eye.
- 04 Impression
Interval, next visit and safety-netting
Read this first: the extended or contracted interval, the date of your next injection, and the red flags to act on before then.
Recognised by major UK insurers
Cover for anti-VEGF injections varies by insurer and by indication — usually funded when medically indicated for wet AMD, DMO or RVO, subject to authorisation limits per eye. We confirm cover before booking.
Frequently asked
Everything we get asked about anti-VEGF injections.
Quick answers on pain, cost, drug choice, and how many injections you actually need.
-
Do the injections hurt?
Most patients describe a brief pressure sensation, not pain. The eye is fully numbed with drops and the injection itself takes under 30 seconds. Soreness and a gritty feeling from the iodine prep are common for a few hours afterwards.
-
How often will I need injections for wet AMD?
A loading course of three monthly injections comes first. After that we use a treat-and-extend regime — extending the interval by two weeks each visit while the OCT stays dry, aiming for 12–16 weeks with aflibercept 8mg or faricimab.
-
Which anti-VEGF drug is best — Eylea, Eylea HD or Vabysmo?
For most treatment-naïve wet AMD, aflibercept 8mg (Eylea HD) or faricimab (Vabysmo) offer the longest realistic intervals. Ranibizumab is still used in myopic CNV and where the newer drugs are unsuitable. The right choice depends on your OCT, other eye conditions and how far you have to travel.
-
How much do private eye injections for macular degeneration cost in the UK?
Roughly £950–£1,400 per aflibercept 2mg injection, £1,200–£1,700 for faricimab and £1,400–£1,900 for aflibercept 8mg. A three-injection loading course typically sits between £2,700 and £5,400 in one eye. We confirm a firm figure before you commit.
-
Are these injections available on the NHS?
Yes — anti-VEGF for wet AMD is a NICE-approved NHS treatment (TA294 aflibercept 2mg, TA924 aflibercept 8mg, TA672 faricimab). Over 800,000 injections are delivered a year in England. The NHS uses fixed intervals under Blueteq; private clinics more often use full treat-and-extend.
-
What are the risks of intravitreal injections?
The serious risk to know is endophthalmitis — a rare intraocular infection occurring in about 1 in 3,000–5,000 injections. Sudden pain, redness or worsening vision in the days after an injection is an emergency. Cataract, retinal detachment and sustained IOP rise are all uncommon.
-
Can I drive home after an injection?
Vision is often blurred for a few hours from the dilating drops and iodine prep. Most clinics advise being driven home or taking a taxi on injection days. By the next morning vision has usually returned to your baseline.
-
What if wet AMD is only in one eye — will the other eye be affected?
Around one in three people with wet AMD in one eye will develop it in the other within five years. We teach you the Amsler grid to check weekly at home and offer rapid re-review if central vision changes in the untreated eye.
Related treatments
Looking for something else?
-
Endophthalmitis treatment
Emergency care for post-injection eye infection.
Learn more -
All tests & procedures
Every test and procedure we arrange.
Learn more -
Rapid diagnostic assessment
A same-week workup when something is not right.
Learn more -
Second-opinion clinics
A fresh consultant view on an existing plan.
Learn more
Nearby in the library